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IMPORTANCE Limited information exists about the epidemiology, recognition, management,
and outcomes of patients with the acute respiratory distress syndrome (ARDS).
OBJECTIVES To evaluate intensive care unit (ICU) incidence and outcome of ARDS and to
assess clinician recognition, ventilationmanagement, and use of adjuncts—for example prone
positioning—in routine clinical practice for patients fulfilling the ARDS Berlin Definition.
DESIGN, SETTING, AND PARTICIPANTS The Large Observational Study to Understand the
Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) was an international,
multicenter, prospective cohort study of patients undergoing invasive or noninvasive
ventilation, conducted during 4 consecutive weeks in the winter of 2014 in a convenience
sample of 459 ICUs from 50 countries across 5 continents.
EXPOSURES Acute respiratory distress syndrome.
MAIN OUTCOMES ANDMEASURES The primary outcomewas ICU incidence of ARDS.
Secondary outcomes included assessment of clinician recognition of ARDS, the application of
ventilatory management, the use of adjunctive interventions in routine clinical practice, and
clinical outcomes from ARDS.
RESULTS Of 29 144 patients admitted to participating ICUs, 3022 (10.4%) fulfilled ARDS
criteria. Of these, 2377 patients developed ARDS in the first 48 hours andwhose respiratory
failure wasmanagedwith invasivemechanical ventilation. The period prevalence ofmild ARDS
was 30.0% (95%CI, 28.2%-31.9%); of moderate ARDS, 46.6% (95%CI, 44.5%-48.6%); and
of severe ARDS, 23.4% (95%CI, 21.7%-25.2%). ARDS represented 0.42 cases per ICU bed over
4weeks and represented 10.4% (95%CI, 10.0%-10.7%) of ICU admissions and 23.4% of
patients requiringmechanical ventilation. Clinical recognition of ARDS ranged from 51.3%
(95%CI, 47.5%-55.0%) inmild to 78.5% (95%CI, 74.8%-81.8%) in severe ARDS. Less than
two-thirds of patients with ARDS received a tidal volume 8 ofmL/kg or less of predicted body
weight. Plateau pressure wasmeasured in 40.1% (95%CI, 38.2-42.1), whereas 82.6% (95%CI,
81.0%-84.1%) received a positive end-expository pressure (PEEP) of less than 12 cmH2O.
Prone positioning was used in 16.3% (95%CI, 13.7%-19.2%) of patients with severe ARDS.
Clinician recognition of ARDSwas associatedwith higher PEEP, greater use of neuromuscular
blockade, and prone positioning. Hospital mortality was 34.9% (95%CI, 31.4%-38.5%) for
those withmild, 40.3% (95%CI, 37.4%-43.3%) for those withmoderate, and 46.1% (95%CI,
41.9%-50.4%) for those with severe ARDS.
CONCLUSIONS AND RELEVANCE Among ICUs in 50 countries, the period prevalence of ARDS
was 10.4% of ICU admissions. This syndrome appeared to be underrecognized and
undertreated and associated with a highmortality rate. These findings indicate the potential
for improvement in themanagement of patients with ARDS.
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A cute respiratory distress syndrome (ARDS) is an acuteinflammatory lung injury, associated with increasedpulmonary vascular permeability, increased lung
weight, and loss of aerated lung tissue.1 Although prior epi-
demiologic studies have provided substantial insights into
ARDS,2-5 there remains limited information about the epide-
miology, recognition, management, and outcomes of pa-
tientswith theARDS, especially in theeraof the currentBerlin
Definition.1 This definition was constructed empirically and
validated using retrospective cohorts1; however, prospective
studiesof theBerlinDefinitionhavebeen limited tosmallnum-
bers of centers and patients.6,7
We set out to address some clinically important ques-
tions regardingARDS. The current incidence andmortality of
ARDS in a large international cohort is not known. Large re-
gional differences have been suggested; for example, the in-
cidenceofARDS inEurope5 is reported tobe 10-fold lower than
in the United States.4 A number of ventilatory interventions,
such as lower tidal volumes,8 higher positive end-expiratory
pressure (PEEP),9 and adjuncts such as prone positioning,10
neuromuscular blockade,11 and extracorporeal membrane
oxygenation12 forARDShavebeenproposed. It isnot clearhow
these interventions are applied in routine practice in the
broader international context. Implementation of effective
therapies may be limited by lack of recognition of ARDS by
clinicians.13,14Understanding the factors associatedwithARDS
recognition and its effect onmanagement could lead to effec-
tive interventions to improve care.
Therefore, we undertook the Large Observational Study
to Understand the Global Impact of Severe Acute Respiratory
Failure (LUNGSAFE) todetermine the intensive careunit (ICU)
epidemiology and outcomes fromARDS, assess clinician rec-
ognitionofARDS,andunderstandhowcliniciansusemechani-
cal ventilation and adjunctive interventions in routine clini-
cal practice.
Methods
Study Design
This study was an international, multicenter, prospective co-
hort study.Theenrollmentwindowconsistedof4 consecutive
winter weeks (February-March 2014 in the Northern hemi-
sphere and June-August 2014 in the Southern hemisphere), as
selected by each ICU. We aimed to recruit a broadly represen-
tative sample of ICUs by public announcements by the Euro-
pean Society of Intensive CareMedicine, by national societies
andnetworks endorsing the study, andbydesignatednational
coordinators (eAppendix 1 in theSupplement). The study ICUs
represent a convenience sampleof those that agreed topartici-
pate in the study and had enrolled at least 1 patient. Different
ICUs from the same hospital were considered as separate cen-
ters; each ICU provided baseline data concerning its resources
(eTable1 intheSupplement).AllparticipatingICUsobtainedeth-
ics committee approval and obtained either patient consent or
ethics committee waiver of consent. We recruited physicians
from each participating country as lead site investigators and
national coordinators. Site investigators (eAppendix 2 in the
Supplement) were also responsible for ensuring data integrity
and validity, and were offered web-based training to enhance
chest x-ray interpretation reliability as part of a substudy.
Patients, Study Design, and Data Collection
All patients, including ICU transfers, admitted toan ICUwithin
the4-weekenrollmentwindowand receiving invasiveornon-
invasiveventilationwere enrolled. Exclusion criteriawere age
younger than 16 years or inability to obtain informed con-
sent, when required. Following enrollment, patients were
evaluated daily for acute hypoxemic respiratory failure, de-
fined as the concurrent presence of (1) ratio of arterial oxygen
tensionto inspired fractionofoxygen(PaO2/FIO2)of300mmHg
or less; (2)newpulmonaryparenchymalabnormalitiesonchest
x-ray or computed tomography; and (3) ventilatory support
with continuous positive airway pressure (CPAP), expiratory
positive airway pressure (EPAP), or positive end-expiratory
pressure (PEEP) of 5 cm H2O or more
Day 1wasdefinedas the first day that acutehypoxemic re-
spiratory failure criteriawere satisfied, irrespective of ICUad-
missiondate.Thecase report form(eAppendix3 in theSupple-
ment) automatically prompted investigators to provide an
expanded data set for days 1, 2, 3, 5, 7, 10, 14, 21, and 28 or at
ICUdischargeordeath.Alldatawere recordedat thesametime,
normally as close as possible to 10 AM each day. Patient out-
comes included date of liberation from mechanical ventila-
tionandvital status at ICUdischarge andat eitherhospital dis-
charge or at day 90, whichever occurred earlier.
Quality Control
At the time of data entry, the site investigators were required
toanswer all queries raisedby the case report formbefore they
couldelectronically finalize apatientdata set. Patientdata sets
that were not finalized were not included in the analysis
(Figure 1). In addition, prior to analysis, all datawere screened
for potentially erroneous data and outliers. These data were
verified or corrected by site investigators. We followed the
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) statement guidelines for observational
cohort studies.15
Identification and Recognition of ARDS
ThediagnosisofARDSwasmadebyacomputeralgorithminthe
analysisphaseof the studyusing the rawdata thatmadeup the
variouscomponentsof theBerlinARDSDefinition: (1)presence
of acutehypoxemic respiratory failure criteria, (2) onsetwithin
1weekof insult,ornew(within7days)orworsening respiratory
symptoms; (3) bilateral airspacedisease on chest x-ray or com-
putedtomographynotfullyexplainedbyeffusions, lobaror lung
collapse,ornodules;and(4)cardiacfailurenottheprimarycause
of acute hypoxemic respiratory failure.
Weassessedclinician recognitionofARDSat2 timepoints.
On day 1 of study entry, site investigators indicated the rea-
sons for thepatient’s hypoxemia,withARDS included as apo-
tential cause. If the answer was “yes,” ARDS was deemed to
have been clinician-recognized on day 1. When patients ex-
ited thestudy, investigatorswereasked if thepatienthadARDS
at any stage during their ICU stay. ARDS was deemed to have
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been clinician-recognized at any point if either question was
answeredpositively. Although clinicianswere offeredpartici-
pation in a substudy to evaluate a training module on chest
x-ray diagnosis of ARDS, theywere not specifically prompted
with the Berlin criteria when answering the questions about
ARDS diagnosis. Criteria for other diagnoses, such as chronic
Figure 1. Flow of Patient Screening and Enrollment
209 Had ARDS
after day 2
8407 Did not develop acute hypoxic respiratory failure
(median, 7/ICU; range, 0-49/ICU)
300 Maintained with noninvasive
ventilation
136 Required invasive ventilation
436 Initially received  noninvasive
ventilation
2377 Received invasive ventilation
(median, 3/ICU; range, 0-27/ICU)
714 Mild ARDS
1106 Moderate ARDS
557 Severe ARDS
2813 Had ARDS on day 1 or 2
4499 With acute hypoxic respiratory
failure (median, 7/ICU; range
0-49/ICU)
3022 Had ARDS (median 5/ICU;
range 0-40/ICU)c
2813 Had ARDS on day 1 or 2
209 Had ARDS after day 2
2377 Included in the primary analysis
1455 Had causes other than ARDS for
acute hypoxic respiratory failure d
582 Pneumonia
392 Heart failure
217 Other
169 COPD
17 Asthma
156 Unknown
22 Unclassified e
12 906 Included in the analysis
(median, 21/ICU; range,
1-177/ICU) 
16 238 Excluded
12 083 Never received invasive ventilation a
660 Records not finalized b
3495 Other reasons a
207 ICUs excluded
175 Did not enroll patients
32 Withdrew
29 144 Patients screened for eligibility
(median, 52/ICU; range,
3-424/ICU) a
435 Hospitals included in the
study (459 ICUs)
635 Hospitals screened for eligibility
(666 ICUs)
a Projected from data provided by 360 intensive care units (ICUs [78%]). Data
specifying other reasons were not collected during the study.
bPatient electronic case report forms thatwerenot fully completewereexcluded.
c Number included in the primary analysis.
d Patients could havemore than one cause for acute hypoxic respiratory failure.
e For unclassified patients it was not possible to determine whether they
fulfilled the criteria for acute respiratory distress syndrome (ARDS) due to
incomplete data.
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obstructive pulmonary disease, pneumonia, etc were left to
clinician discretion.
ARDS Severity andMechanical Ventilation Parameters
Patients with ARDS undergoing invasive ventilation were cat-
egorized on the day of ARDS diagnosis based on their
PaO2/FIO2 ratio into mild (200 <PaO2/FIO2 ≤300 mm Hg),
moderate (100 <PaO2/FIO2 ≤200 mm Hg), and severe
(PaO2/FIO2 <100 mm Hg) based on the Berlin Definition.1
Given the lack of clarity in the Berlin Definition regarding the
severity classification of patients managed with noninvasive
ventilation, and the difficulty in comparing noninvasive ven-
tilation settings to invasivemodes, we excluded patients ven-
tilated on noninvasive ventilation from the analyses pertain-
ing to severity, ventilator management or outcome. To
ensure a more homogenous data set, we restricted subse-
quent analyses to the large subset of patients (93.1%) fulfill-
ing ARDS criteria on day 1 or 2 from onset of acute hypoxemic
respiratory failure.
Invasive ventilator-free dayswere calculated as the num-
ber of days fromweaning from invasive ventilation to day 28.
Patients who died before weaning were considered to have a
ventilator-free-day value of 0. Driving pressure was defined
as plateau pressure (Pplat) minus PEEP.
Patientswere considered to have no evidence for sponta-
neous ventilation when set and measured respiratory rates
were equal.
Calculation of Period Prevalence
and Per-ICU-Bed ARDS Incidence
TheperiodprevalenceofpatientswithARDSwascalculatedby
dividing the number of patients fulfilling ARDS criteria by the
totalnumberofpatientsadmittedtothe ICUinthe28-daystudy
period (ie, 29 160). The number of patients with ARDS per ICU
bedover the 4-week studyperiodwas calculated as number of
patients with ARDS/number of ICU beds available.
ICU Enrollment and Statistical Analysis
The primary outcome was to determine the ICU incidence of
ARDS. Secondary outcomes included assessment of clinician
recognition of ARDS, the application of ventilatory manage-
ment, the use of adjunctive interventions in routine clinical
practice, and the outcomes from ARDS. We wished to enroll
at least 1000 patients with ARDS. Assuming a 30%mortality,
300 deaths would allow us to evaluate at least 30 associated
variables inmultivariablemodels.16Priorepidemiological stud-
ies reportedanARDS incidence rangingbetween2.2%and19%
of ICUpatients.2-5Basedonaconservativeapriori estimate that
5% of ICU admissionswould have ARDS and projecting that a
medium-sized ICUadmits 50patients permonth,weplanned
to enroll at least 500 ICUs worldwide.
Descriptive statistics included proportions for categorical
andmean (standard deviation) or median (interquartile range
[IQR]) forcontinuousvariables.Theamountofmissingdatawas
low,withtheexceptionofplateaupressurePplat andarterialoxy-
gen saturation (SaO2), and is detailed in eTable 2 in the Supple-
ment).Noassumptionsweremade formissingdata.Datawere
unadjusted unless specifically stated otherwise. Proportions
were compared using χ2 or Fisher exact tests and continuous
variables were compared using the t test or Wilcoxon rank-
sumtest, as appropriate. To evaluate variables associatedwith
clinician recognitionofARDS, covariatesdeterminedapriori to
be associated with ARDS recognition and covariates associ-
ated with ARDS recognition with P < .20 in bivariate analyses
were entered into multivariable regression models with vari-
able selection based on a stepwise backward elimination pro-
Table 1. Characteristics of PatientsWith Acute Respiratory Distress
Syndrome
Parameter Value
No. of patients
ARDS 3022
ARDS in first 48 h after AHRF 2813
No longer fulfill ARDS criteria after 24 h,
No. (%) [95% CI]
486 (17) [15.9-18.7]
Clinician recognition of ARDS,
No. (%) [95% CI]
1820 (60) [59-62.0]
Age, mean (95% CI)y 61.5 (60.9-62.1)
Women, No. (%) 1151 (38)
Height, mean (95% CI), cm 168 (167.6-168.4)
Weight, mean (95% CI), kg 78.0 (77-79)
Chronic disease, No. (%)
COPD 657 (21.7)
Diabetes 657 (21.7)
Immunoincompetence 365 (12.1)
Chronic cardiac failure 314 (10.4)
Chronic renal failure 306 (10.1)
Active neoplasm 258 (8.5)
Hematological disease 142 (4.7)
Risk factor for ARDS, No. (%)a
Pneumonia 1794 (59.4)
Extrapulmonary sepsis 484 (16.0)
Aspiration 430 (14.2)
Noncardiogenic shock 226 (7.5)
Trauma 127 (4.2)
Blood transfusion 118 (3.9)
Pulmonary contusion 97 (3.2)
Inhalation 72 (2.3)
Drug overdose 56 (1.9)
Pulmonary vasculitis 41 (1.4)
Burn 9 (0.3)
Drowning 2 (0.1)
Other risk factor 82 (2.7)
No risk factor 252 (8.3)
Duration of invasive mechanical ventilation,
median (IQR), d
8 (4-16)
Duration of ICU stay, median (IQR), d 10 (5-19)
ICU survival, No. (%) [95% CI] 1994 (66.0) [64.3-67.7]
Duration of hospital stay, median (IQR), d 17 (9-32)
Hospital survival, No. (%) [95% CI]b 1826 (60.4) [58.7-62.2]
Abbreviations: AHRF, acute hypoxemic respiratory failure; ARDS, acute
respiratory distress syndrome; COPD, chronic obstructive pulmonary disease;
ICU, intensive care unit; IQR (interquartile range).
a Total is greater than 100%,becausepatients couldhavemore than 1 risk factor.
bData are missing for 10 patients.
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cedure using P values. The association of clinician recognition
withventilatorymanagementofARDSwasdeterminedfor tidal
volume, PEEP, Pplat measurement, and use of prone position-
ingandneuromuscularblockade inseparatemultivariablestep-
wise backward logistic ormultiple linear regressionmodels as
appropriate. We did not perform any longitudinal data analy-
ses. A Kaplan-Meier estimate of the cumulative probability of
unassistedbreathingandsurvival today28wasperformed.Pa-
tients discharged from the hospital before day 28 were as-
sumed alive at this time point. Statistical analyses were per-
formedwithR3.2.3(http://www.R-project.org).AllPvalueswere
2-sided,withPvalues <.05 considered statistically significant.
Thestudyprotocol, case report formandfull statistical analysis
plan are included in eAppendix 3 in the Supplement.
Results
Participating ICUs and Patients Enrolled
Six hundred sixty-six ICUs registered for the study. Following
data verification and elimination of nonrecruiting sites, 459
ICUs from 50 countries were included in the final analysis
(eTable 1 and eTable 3 in the Supplement). Of the 29 144 pa-
tients admitted to these ICUs during the enrollment period,
13 566 patients receiving ventilatory support were enrolled.
Complete data sets from 12 906 patients were analyzed
(Figure 1). Table 1 outlines their key characteristics.
Characteristics of Patients Enrolled
Of 4499 patients with acute hypoxemic respiratory failure,
3022 (67.2%) fulfilled ARDS criteria during their ICU stay. Of
these, 2813 (93.1%) developedARDS at day 1 (n = 2665) or day
2 (n = 148), whereas 209 patients (6.9%) developed ARDS af-
ter day2of acutehypoxemic respiratory failure (Figure 1). The
436patients (14.4%)withARDSwhoreceivednoninvasiveven-
tilation were excluded from analyses regarding ARDS sever-
ity, mechanical ventilation settings, and outcome.
ICU Incidence of ARDS
ARDS represented 10.4% (95% CI, 10.0%-10.7%) of total ICU
admissions and23.4% (95%CI, 21.7%-25.2%)of all patients re-
quiring mechanical ventilation and constituted 0.42 cases/
ICU bed over 4 weeks. There was some geographic variation,
with Europe having an incidence of 0.48 cases/ICU bed over
4weeks;NorthAmerica,0.46; SouthAmerica,0.31;Asia,0.27;
Africa, 0.32; and Oceania, 0.57 cases/ICU bed per 4 weeks.
Table 2. Organizational and Patient Factors AssociatedWith Clinician Recognition of ARDS in Invasively Ventilated Patients
ARDS Recognized,
No./Total No. (%)
Absolute Difference
(95% CI)
Bivariate OR
(95% CI) P Valuea
Multivariable OR
(95% CI) P Valueb
No. of patients/staff physician,
for each additional patient
−1.20 (−0.74 to −1.66)c 0.960 (0.945 to 0.976) <.001 0.959 (0.942 to 0.977) <.001
No. of patients/nurse, for each
additional patient
−0.34 (−0.55 to −0.13)c 0.911 (0.860 to 0.957) <.001 0.920 (0.870 to 0.968) .002
Age, per year −4.03 (−5.43 to −2.65)c 0.985 (0.980 to 0.990) <.001 0.987 (0.980 to 0.993) <.001
Predicted body weight per kg −1.27 (−2.18 to −0.36)c 0.989 (0.980 to 0.997) .006 0.984 (0.974 to 0.993) <.001
Nonpulmonary SOFA per point 0.81 (0.48 to 1.12)c 1.054 (1.031 to 1.077) <.001 1.057 (1.030 to 1.085) <.001
PaO2:FIO2 ratio, per mm Hg −30.0 (−35.5 to −24.4)c 0.993 (0.992 to 0.995) <.001 0.993 (0.992 to 0.995) <.001
Medical or surgical Admission
with trauma
No 1477/2274 (65.0) 1 [Reference] 1 [Reference]
Yes 48/103 (46.6) −18.4 (−28.7 to −8.0) 0.471 (0.316 to 0.700) <0.001 0.539 (0.334 to 0.868) .011
Neoplastic or immune or
hematologic disease
No 1173/1892 (62.0) 1 [Reference] 1 [Reference]
Yes 352/485 (72.6) 10.6 (6.0 to 15.1) 1.623 (1.305 to 2.027) <.001 1.396 (1.079 to 1.816) .012
Pneumonia
No 440/1002 (43.9) 1 [Reference] 1 [Reference]
Yes 963/1375 (70.0) 26.1 (22.2 to 30.0) 1.830 (1.544 to 2.170) <.001 1.339 (1.073 to 1.670) .01
Pancreatitis
No 844/2328 (36.3) 1 [Reference] 1 [Reference]
Yes 41/49 (83.7) 47.4 (36.9 to 58.0) 2.915 (1.436 to 6.733) .006 3.506 (1.439 to 10.543) .01
ARDS risk factors
Yes 1454/2187 (66.5) 1 [Reference] 1 [Reference]
No 71/190 (37.4) −29.1 (−36.3 to −22.0) 0.301 (0.220 to 0.408) <.001 0.408 (0.280 to 0.591) <.001
With heart failure
No 1347/2027 (66.5) 1 [Reference] 1 [Reference]
Yes 178/350 (50.9) −15.6 (−21.2 to −10.0) 0.522 (0.415 to 0.657) <.001 0.496 (0.377 to 0.652) <.001
Abbreviations. ARDS, acute respiratory distress syndrome; PaO2/FIO2; partial
pressure of oxygen to fraction of inspired oxygen; SOFA, Sequential Organ
Failure Assessment.
a Bivariate analysis.
bAll variables included in themultivariable analysis are reported in this Table.
c These values are themean difference (95% CI).
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Recognition of ARDS
ARDS was underdiagnosed, with 60.2% of all patients with
ARDS being clinician-recognized. Clinician recognition of
ARDS ranged from 51.3% (95% CI, 47.5%-55.0%) for mild
ARDS to 78.5% (95% CI, 74.8%-81.8%) for severe ARDS
(eTable 4 in the Supplement). Clinician recognition of ARDS
at the time of fulfillment of ARDS criteria was 34.0% (95%
CI, 32.0-36.0), suggesting that diagnosis of ARDS was fre-
quently delayed.
A multivariable analysis including variables from the
bivariable analyses (eTable 5 in the Supplement), revealed
several patient and organizational factors associated with
clinician recognition of ARDS. Higher nurse-to-patient
ratios, higher physician-to-patient ratios, younger patient
age and a lower PaO2/FIO2 ratio, and the presence of pneu-
monia or pancreatitis were factors independently associated
with higher probability of clinician recognition (Table 2).
Absence of a risk factor and presence of concomitant
Table 3. Baseline Characteristics of PatientsWith Acute Respiratory Distress Syndrome TreatedWith Invasive Ventilation by Severity Category
at Diagnosis
Parameter
All
(N = 2377)
Mild
(n = 714)
Moderate
(n = 1106)
Severe
(n = 557) P Valuea
Age, median (IQR), y 61 (61-62) 61 (60-63) 62 (62-63) 57 (55-58) <.001
No longer meet ARDS criteria after 24 h,
No. (%) [95% CI]
486 (17.3)
[15.9-18.7]
190 (26.6)
[23.4-30.0]
152 (13.7)
[11.8-15.9]
71 (12.8)
[10.1-15.8]
<.001
Severity of illness, mean (95% CI), SOFA scoreb
Day 1 10.1 (9.9-10.2) 8.8 (8.6-9.1) 10.2 (9.9-10.4) 11.4 (11.1-11.8) <.001
Day 1 nonpulmonaryc 6.9 (6.7-7.0) 6.7 (6.4-7.0) 6.9 (6.7-7.1) 7.0 (6.7-7.4) .34
Worst 11.1 (10.9-11.3) 10.3 (10.0-10.6) 11.8 (11.5-12.0) 13.0 (12.6-13.3) <.001
Worst nonpulmonary 8.0 (7.8-8.2) 8.0 (7.7-8.3) 8.7 (8.4-8.9) 9.0 (8.4-8.9) <.001
Ventilator settings, first day of ARDS
FIO2, mean (95% CI) 0.65 (0.64-0.65) 0.48 (0.47-0.50) 0.62 (0.61-0.63) 0.90 (0.88-0.91) <.001
Median (IQR) 0.6 (0.45-0.85) 0.4 (0.4-0.5) 0.6 (0.5-0.7) 1 (0.8-1)
Set respiratory rate, mean (95% CI), 1/min 18.6 (18.3-19.0) 17.4 (16.9-17.8 18.4 (18.0-18.5) 20.4 (19.2-21.6) <.001
Total respiratory rate, mean (95% CI), 1/min 20.8 (21.5-21.2) 19.5 (19.0-19.9) 20.7 (20.3-21.1) 22.7 (21.5-23.8) <.001
VT, mean (95% CI), mL/kg PBW 7.6 (7.5-7.7) 7.8 (7.6-7.9 7.6 (7.5-7.7) 7.5 (7.3-7.6) .02
Control vent mode 7.5 (7.4-7.6) 7.6 (7.5-7.8) 7.4 (7.3-7.6) 7.4 (7.2-7.6) .06
Spontaneous vent mode 7.9 (7.8-8.1) 7.9 (7.7-8.2) 8.0 (7.7-8.2) 7.7 (7.4-8.1) .55
P value (control vs spont mode) <.001 .049 <.001 .053
Set PEEP, mean (95% CI), cm H2O 8.4 (8.3-8.6) 7.4 (7.2-7.6) 8.3 (8.1-8.5) 10.1 (9.8-10.4) <.001
Peak pressure, mean (95% CI), cm H2Od 27.0 (26.7-27.4) 24.7 (24.1-25.4) 26.9 (26.5-27.4) 30.3 (29.6-30.9) <.001
Patients in whom PPLAT measured, No. (%)
Among all invasively ventilated patients,
No. (%) [95% CI]
954 (40.1)
[38.2-42.1]
260 (36.4)
[32.9-40.1]
463 (41.9)
[38.9-44.8]
231 (41.5)
[37.3-45.7]
.05
Among patients with controlled ventilation,
No. (%) [95% CI]
756 (48.5)
[46.0-51.0]
198 (46.1)
[41.3-51.0]
363 (49.8)
[46.1-53.5]
195 (48.5)
[43.5-53.5]
.49
PPLAT, mean (95% CI), cm H2Oe 23.2 (22.6-23.7) 20.5 (19.8-21.3) 23.1 (22.6-23.7) 26.2 (25.2-27.1) <.001
Standardized minute ventilation,
mean (95% CI), l/minf
10.8 (10.6-11.0) 9.3 (9.1-9.6) 10.7 (10.5-11.0) 12.8 (12.3-13.3) <.001
Spontaneous ventilation, No. (%) [95% CI] 723 (30.4
[8.6-32.3]
260 (36.4)
[32.9-40.0]
336 (30.4)
[29.7-35.3]
127 (22.8)
[19.3-26.5]
<.001
Gas exchange, first day of ARDS
PaO2/FIO2 ratio, mean (95% CI), mmHg 161 (158-163) 246 (244-248) 149 (147-150) 75 (74-77) <.001
SpO2, mean (95% CI) 95 (94-95) 97 (97-98) 95 (95-96) 90 (89-91) <.001
Median (IQR) 96 (93-98) 98 (96-99) 96 (94-98) 92 (88-95)
PaCO2, mean (95% CI), mm Hg 46.0 (45.4-46.6) 41.5 (40.7-42.2) 45.8 (44.9-46.6) 52.2 (50.7-53.7) <.001
pH, mean (95% CI) 7.33 (7.32-7.33) 7.36 (7.36-7.37) 7.33 (7.32-7.33) 7.27 (7.26-7.29) <.001
Abbreviations: ARDS, acute respiratory distress syndrome; IQR, interquartile
range; PBW; predicted body weight; PEEP, positive end-expiratory pressure;
PaO2/FIO2, partial pressure of oxygen to fraction of inspired oxygen; PPLAT,
plateau pressure; SOFA, Sequential Organ Failure Assessment; VT, tidal volume;
SpO2, peripheral arterial oxygen saturation.
a P value represents comparisons across the ARDS severity categories for each
variable.
b For all SOFA scores for which data points were missing, this value was omitted
and the denominator adjusted accordingly.
c The nonpulmonary SOFA score and the pulmonary component of the score
was omitted and the denominator adjusted accordingly.
d For peak pressure measurements, patients receiving high-frequency
oscillatory ventilation (HFOV) or extracorporeal membrane oxygenation
(ECMO) were excluded.
e Plateau pressure values are limited to patients in whom this value was
reported and in whom either an assist control mode was used or in whom
amode permitting spontaneous ventilation was used. The set and total
respiratory rates were equal. Patients receiving HFOV or ECMOwere
also excluded.
f Standardizedminute ventilation = minute ventilation × PaCO2/40mmHg.
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Table 4. Use of Adjunctive andOther OptimizationMeasures in Invasively Ventilated Patients
With Acute Respiratory Distress Syndromea
Patients of No. (%) [95% CI]
P Valueb
All
(n = 2377)
Milda
(n = 498)
Moderatea
(n = 1150)
Severea
(n = 729)
Neuromuscular
blockade
516 (21.7)
[20.1-23.4]
34 (6.8)
[4.8-9.4]
208 (18.1)
[15.9-20.4 ]
274 (37.8)
[34.1-41.2]
<.001
Recruitment
maneuvers
496 (20.9)
[19.2-22.6]
58 (11.7)
[9.0-14.8]
200 (17.4)
[15.2-19.7]
238 (32.7)
[29.3-36.2]
<.001
Prone positioning 187 (7.9)
[6.8-9.0]
5 (1.0)
[0.3-2.3]
63 (5.5)
[4.2-7.0]
119 (16.3)
[13.7-19.2]
<.001
ECMO 76 (3.2)
[2.5-4.0]
1 (0.2)
[0.05-1.2]
27 (2.4)
[1.6-3.4]
48 (6.6)
[4.9-8.6]
<.001
Inhaled vasodilators 182 (7.7)
[6.6-8.8]
17 (3.4)
[02.0-5.4]
70 (6.1)
[4.8-7.6]
95 (13.0)
[10.7-15.7]
<.001
HFOV 28 (1.2)
[0.8-1.7]
3 (0.6)
[0.1-1.7]
14 (1.2)
[0.7-2.0]
11 (1.5)
[0.8-2.7]
.347
None of the above 1431 (60.2)
[58.2-62.2]
397 (79.7)
[75.9-83.2]
750 (65.2)
[62.4-68.0]
284 (39.0)
[35.4-42.6]
<.001
Esophageal pressure
catheter
19 (0.8)
[0.04-1.4]
2 (0.4)
[0.04-1.4]
8 (0.7)
[0.3-1.3]
9 (1.2)
[0.6-2.3]
.233
Tracheostomy 309 (13.0)
[11.6-14.4]
48 (9.6)
[7.1-12.6]
155 (13.5)
[11.6-15.6]
106 (14.5)
[12.1-17.3]
.034
High-dose
corticosteroidsc
425 (17.9)
[16.4-19.5]
61 (12.3)
[9.5-15.5]
194 (16.9)
[14.7-19.2]
170 (23.3)
[20.3-26.6]
<.001
Pulmonary artery
catheter
107 (4.5)
[3.7-5.4]
9 (1.8)
[0.8-3.4]
53 (4.6)
[3.4-6.0]
45 (6.2)
[4.5-8.2]
.001
Abbreviations: ARDS, acute
respiratory distress syndrome;
ECMO, extracorporeal membrane
oxygenation; HFOV, high-frequency
oscillatory ventilation; PEEP, positive
end-expiratory pressure.
a For this analysis, ARDS severity was
defined based on the patients’
worst severity category over the
course of their ICU stay in patients
who developed ARDS on day 1 or 2.
bP value represents comparisons
across the ARDS severity categories
for each variable.
c High-dose corticosteroids was
defined as doses that were equal
to or greater than the equivalent
of 1 mg/kg of methylprednisolone.
Table 5. Outcome of Invasively Ventilated Patients by Acute Respiratory Distress Syndrome Severity at Diagnosis
Parameter
All
(n = 2377)
Mild
(n = 714)
Moderate
(n = 1106)
Severe
(n = 557) P Valuea
Progression of ARDS severity,
No (%) [95% CI]b
Progression to moderatec 184 (25.8)
[22.6-29.1]
N/A N/A
Progression to severec 32 (4.5)
[3.1-6.3]
140 (12.7)
[10.8-14.8]
N/A
Death in the 1st wk without category change 63 (8.8)
[6.8-11.1]
126 (11.4)
[9.6-13.4]
117 (21.0)
[17.7-24.6]
Invasive ventilation-free days to day 28,
median (IQR), dd
10 (0-22) 16 (0-24) 11 (0-21) 0 (0-18) <.001
Duration of invasive ventilation,
median (IQR), d
All patients 8 (4-15) 7 (3-14) 8 (4-16) 9 (4-16) .04
Surviving patients 8 (4-15) 6 (3-13) 8 (4-15) 11 (6-18) <.001
ICU length of stay, median (IQR), d
All patients 10 (5-20) 10 (5-19) 11 (6-20) 11 (5-19) .39
Surviving patients 11 (7-21) 10 (6-19) 12 (7-21) 14 (7-23) .03
ICU mortality, No. (%) [95% CI] 838 (35.3)
[33.3-37.2]
212 (29.7)
[26.4-33.2]
387 (35.0)
[32.2-37.9]
239 (42.9)
[38.8-47.1]
<.001
Day 28 mortality, No. (%) [95% CI] 828 (34.8)
[32.9-36.8]
211 (29.6)
[26.2-33.0]
389 (35.2)
[32.4-38.1]
228 (40.9)
[36.8-45.1]
<.001
Hospital length of stay, median (IQR), d
All patients 17 (8-33) 18 (10-33) 17 (8-33) 16 (6-31) .22
Surviving patients 23 (14-40) 23 (14-40) 22 (13-40) 26 (14-43) .41
Hospital mortality, No. (%) [(95% CI] 952 (40.0)
[38.1-42.1]
249 (34.9)
[31.4-38.5]
446 (40.3)
[37.4-43.3]
257 (46.1)
[41.9-50.4]
<.001
Abbreviations: ARDS, acute respiratory distress syndrome, ICU, intensive care
unit; IQR, interquartile range.
a P value represents comparisons across the ARDS severity categories
for each variable.
b Initial ARDS severity determined fromworst partial pressure of oxygen
to fraction of inspired oxygen ratio within first 24 hours following
ARDS diagnosis.
c Most severe is calculated for time period up to day 7 postdiagnosis of ARDS.
Analysis was limited to the first 7 days due to the less frequent sampling
after that day.
d In patients in whom death occurs while receiving invasive mechanical
ventilation, invasive ventilation-free days are counted as 0.
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cardiac failure were associated with reduced likelihood of
clinician recognition of ARDS (Table 2). The mean tidal vol-
ume was 7.5 mL/kg (95% CI, 7.4-7.6 mL/kg) of predicted
body weight (PBW) among patients whose physicians recog-
nized ARDS, marginally lower than that of 7.7 mL/kg (95%
CI, 7.6-7.9 mL/kg) in patients whose ARDS was not recog-
nized (P = .01). The mean PEEP level was 8.9 cm H2O (95%
CI, 8.8-9.1 cm H2O) in patients whose ARDS was recognized,
higher than that of 7.5 cm H2O (95% CI, 7.3-7.7 cm H2O) in
patients whose ARDS was not recognized (P < .001). Physi-
cians who recognized ARDS used adjunctive treatments
more than physicians who did not (43.9% vs 21.7%,
P < .001; eTable 4 in the Supplement). After adjusting for
potentially confounding variables, there was no statistically
significant association between clinician-recognized ARDS
and tidal volumes (eTable 6 in the Supplement) or Pplat
recording (eTable 7 in the Supplement). In contrast, clini-
cian recognition of ARDS was statistically associated with
the use of higher levels of PEEP, and greater use of prone
positioning and neuromuscular blockade (eTables 8-10 in
the Supplement).
ARDS Severity
A total of 2377 patients developed ARDS in the first 48 hours
of acute hypoxemic respiratory failure and received invasive
mechanical ventilation. The period prevalence of mild ARDS
was 30.0% (95% CI, 28.2%-31.9%); moderate, 46.6% (95%
CI, 44.5%-48.6%); and severe, 23.4% (95% CI, 21.7%-25.2%)
(Figure 1). Ventilator management differed among the ARDS
severity groups, while the use of adjunctive measures
increased and mortality was higher with greater ARDS sever-
ity (Table 3, Table 4, and Table 5). At diagnosis, increasing
ARDS severity was paralleled by worsening Sequential Organ
Failure Assessment (SOFA) scores, which was largely
accounted for by the pulmonary component. The nonpul-
monary component of the SOFA score was higher in patients
with an increased ARDS severity category (Table 3). The
PaCO2 increased and pH decreased in patients with increased
ARDS severity category (Table 3, eFigure 1A-B in the Supple-
ment). Three hundred sixteen patients (13.3%) with ARDS
had a PaCO2 of 60 mmHg or higher. However, the extent and
severity of hypercapnia was relatively modest, even in
severe ARDS.
Mechanical Ventilation in ARDS
Ventilator management varied with ARDS severity (Table 3).
However, the decrease in tidal volume and increase in PEEP,
frommild tomoderate to severe ARDS,while statistically sig-
nificant,was clinicallymodest (Table 3). InpatientswithARDS
35.1% (95% CI, 33.1%-37.1%) received a tidal volume of more
than 8 mL/kg PBW (Figure 2A and eFigure 1C in the Supple-
ment),while 82.6% (95%CI, 81.0%-84.1%) received aPEEPof
less than 12 cm H2O.
The distribution of Pplat differed significantly with ARDS
severity (Figures 2B and eFigure 1D in the Supplement). Pplat
was measured in 40.1% (95% CI, 46.0%-51.0%) of patients,
irrespective of ARDS severity. This rose to 48.5% (95% CI,
46.0%-51.0%) of patients in whom there was no evidence for
Figure 2. Ventilation Parameters in PatientsWith ARDS
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spontaneous ventilation. Two-thirds of patients in whom
Pplat was reported received protective mechanical ventilation
as defined by a tidal volume of 8 mL/kg of PBW or less and
a Pplat of 30 cm H2O or less (Figure 2C). In patients in whom
Pplat was measured, 91.9% (95% CI, 88.1%-94.9%) of those
receiving a tidal volume of more than 8 mL/kg PBW had
a Pplat of 30 cm H2O or less (Figure 2C). Less than 3% of
patients received a tidal volume of more than 8 mL/kg and
had a Pplat pressure of more than 30 cm H2O (Figure 2C).
Therewasnorelationshipbetween tidalvolumeandeither
peak inspiratory pressure, Pplat or lung compliance (Figure 3A
and eFigure 2 in the Supplement). Tidal volume was signifi-
cantlyhigher inpatients ina spontaneousbreathingmode (7.5;
95% CI, 7.4-7.6 vs 7.9; 95% CI, 7.8-8.1 mL/kg PBW, P < .001;
Table 3).
Positiveend-expiratorypressure levelswere relatively low
(Table 3) and were higher in patients with higher peak inspi-
ratory pressure and higher Pplat. In addition, no relationship
was found between PEEP and the PaO2/FIO2 ratio, FIO2
(Figure 3B) or lung compliance (eFigure 2 in the Supple-
ment). In contrast, therewas an inverse relationship between
FIO2 and SpO2, suggesting that clinicians usedFIO2 to treat hy-
poxemia (Figure 3C).
Use of AdjunctiveMeasures
The use of adjunctive treatments in patients with ARDS on
day 1 or 2 was relatively low but increased with ARDS sever-
ity (Table 4). Continuous neuromuscular blocking agents,
high-dose steroids, and recruitment maneuvers were the
most frequently used adjuncts. In patients with severe
ARDS, continuous neuromuscular blockade was used in
37.8% (95% CI, 34.1%-41.2%), prone position in 16.3% (95%
CI, 13.7%-19.2%), and recruitment maneuvers in 32.7% (95%
CI, 29.3%-36.2%).
ARDSOutcomes
Severity of ARDS worsened in 356 (19.6%, 95% CI, 17.8%-
21.5%) patients with mild or moderate ARDS (Table 5).
There was a decreased likelihood of unassisted breathing
(Figure 4A) and survival (Figure 4B) at day 28 with increas-
ing severity. Overall, unadjusted ICU and hospital mortality
from ARDS were 35.3% (95% CI, 33.3%-37.2%) and 40.0%
(95% CI, 38.1%-42.1%), respectively (Figure 4 and Table 5).
The number of ventilator-free days decreased (eFigure 3 in
the Supplement), and the length of ICU—but not hospital—
stay, increased with greater ARDS severity category. Both
ICU and hospital survival decreased with increased ARDS
severity (Table 5). Patients with a driving pressure (ie, Pplat-
PEEP) of more than 14 cm H2O on day 1 had a worse out-
come (Figure 4C). There was a direct relationship between
both plateau and driving pressure quintile and mortality
rate (Figure 5).
Discussion
In this prospective study carried out in 459 ICUs in 50 coun-
tries in 5 continents, ARDS appeared to represent an impor-
Figure 3. Mechanical Ventilation Settings in Early Acute Respiratory
Distress Syndrome
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tant public health problem globally, with some geographic
variation and with a very high mortality of approximately
40%. A major finding was the underrecognition of ARDS by
clinicians, the low use of contemporary ventilatory strate-
gies and adjuncts, and the limited effect of physician diag-
nosis of ARDS on treatment decisions. These findings indi-
cate the potential for improvement in management of
patients with ARDS.
In this study, the geographic variation in ARDS inci-
dence ranged from 0.27 to 0.57 cases per ICU bed per 4
weeks and prcentage of ICU admissions. Because we could
not estimate the population served by the ICUs in this
study, we could not calculate population incidence for
ARDS; therefore, relatively little can be inferred about the
burden of ARDS in participating countries. The nearly 2-fold
variation in ICU incidence in this study and the known
variation in ICU resources internationally may well explain
the variability in ARDS studies that involved specific geo-
graphic populations,5 with the highest estimates in the
United States4,17 and Australia.18,19 Our ICU incidence data
are concordant with other estimates using similar
approaches that have generated reliable population inci-
dence data.20
These results suggest that ARDS continues to be under-
recognized by clinicians in the era of the Berlin Definition,
similar to previous findings using the American-European
consensus conference (AECC) definition.14,21-23 A key fea-
ture of our study design was that data were collected for
each component of the Berlin Definition in all patients with
hypoxemia breathing with the aid of a ventilator, which
allowed us to identify patients with ARDS from the raw
data. We chose this approach to enable a more robust evalu-
ation of the incidence, as well to assess clinician recognition
of ARDS. The rate of clinician recognition of ARDS was low,
with 40% of all cases not being diagnosed. Clinician recog-
nition rates increased with increasing disease severity but
was still less than 80% in severe ARDS. Independent factors
contributing to clinician recognition were younger patient
age, lower predicted body weight, the presence of extrapul-
monary sepsis or pancreatitis, and greater disease severity.
Conversely, the absence of a risk factor for ARDS was associ-
ated with underrecognition of ARDS. Lower numbers of
nurses and physicians per ICU patient were both associated
with reduced clinician recognition of ARDS. It is possible
that the way in which the data were collected contributed,
in part, to clinician underrecognition of ARDS. Specifically,
it is possible that the ICU clinician knew that the patient had
ARDS, but this was not made known to the site investigators
or reported in the patient chart. However, not indicating the
diagnosis of ARDS in the chart constitutes a form of under-
recognition. In addition, that the study had an explicit focus
on ARDS, that all participants were offered online training
on ARDS diagnosis, and that the case report form asked at 2
separate points in the study if the patient had ARDS, make
this possibility less likely.
It is unclear whether clinician recognition of ARDS
affects outcome because recognition may be only one of a
number of barriers to the use of ventilatory and adjunctive
Figure 4. Outcome FromAcute Respiratory Distress Syndrome
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treatment strategies, while the sickest patients are more fre-
quently diagnosed.14,24 After adjusting for potential con-
founders, clinician diagnosis of ARDS was not indepen-
dently associated with the use of lower tidal volume.
Conversely, clinician diagnosis of ARDS was significantly
associated with the use of higher PEEP, prone positioning,
and neuromuscular blockade. Although the reasons for this
are unclear, clinicians do not appear influenced by the pres-
ence or absence of ARDS for setting tidal volume and may
be motivated by other factors (eg, perceived comfort, pH,
PaCO2, etc).
Our data appear to demonstrate the predictive validity
of the Berlin Definition, and are consistent with a recent
observational study.7 Increasing ARDS severity was associ-
ated with longer ICU stay, fewer days of invasive ventilation,
longer hospital stays, and higher mortality. Patients with
severe ARDS were younger, had fewer comorbidities but
had a significantly worse outcome. The proportion of
patients in each severity category was similar to that deter-
mined in retrospective analyses.1
ARDS appears to be undertreated in terms of the use of
optimal, proven, or recommended approaches to mechani-
cal ventilation and regarding the use of some adjunctive
measures. Plateau pressure was reported in only 40.1% of all
patients with ARDS, which increased to 48.5% of patients in
whom there was no evidence for spontaneous ventilation.
Although it is possible that patients in whom plateau pres-
sure was measured were ventilated differently, this did not
appear to be the case, at least in terms of tidal volume. We
found no evidence to suggest that lower tidal volumes or
higher PEEP were used in patients with a less compliant
respiratory system or greater ARDS severity as reported in
prior studies.22 Low tidal volume ventilation was the most
frequently used intervention, but more than one-third of all
patients with ARDS received a tidal volume of more than 8
mL/kg of PBW, and approximately 60% received a tidal vol-
ume of more than 7 mL/kg of PBW. This finding is consistent
with recent nonprotocolized RCTs in which patients
received larger tidal volumes than expected.12,25 In our
study, PEEP was relatively low and constant across the spec-
trum of ARDS severity, with more than 80% of patients with
ARDS receiving PEEP of 12 cm H2O or less. Hypoxemia
appeared to be treated predominantly by increasing
FIO2. High levels of permissive hypercapnia were infre-
quent. Adjunctive measures were used infrequently; this
appeared to be the case for less expensive interventions
such as prone positioning and neuromuscular blockade, as
well as for expensive and invasive technologies such as
extracorporeal membrane oxygenation. It is possible that
the relatively low use of adjunctive measures such as neuro-
muscular blockade or prone positioning reflects ongoing
uncertainty about the quality of evidence supporting these
interventions.
ARDS continues to have a high mortality, despite
advances in supportive care. There was a significant
increase in mortality with each increase in ARDS severity
category. Overall, 40% of patients with ARDS died in the
hospital. Although detailed analyses of the factors contrib-
uting to outcome are beyond the scope of this article, we
also confirmed a recent report26 suggesting that higher driv-
ing pressure is associated with increased risk of death;
albeit, our data should be interpreted cautiously as Pplat was
available in a minority of patients.
This study has a number of limitations. Our focus on
winter months, while allowing us to examine the burden of
ARDS during the same season across the globe, may over-
state ICU incidence figures for ARDS, due to specific dis-
eases such as influenza.27 In addition, despite enrolling a
large number of ICUs from around the world, our conve-
nience sample may be prone to selection biases that may
limit generalizability; therefore, we are unable to calculate
population-based incidence figures for ARDS. Similar to
other epidemiological studies, we did not have access to the
source data for the patients in the enrolling ICUs, so it is
possible that not all patients with ARDS in participating cen-
ters were enrolled. However, enrollment of patients with
ARDS from participating ICUs met expectations based on
their recorded 2013 admission rates, while data from lower
Figure 5. Driving Pressure and Plateau Pressure andOutcome FromARDS
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recruiting ICUs was not different from that from higher
enrolling ICUs, suggesting the absence of reporting biases.
To ensure data quality, we instituted a robust data quality-
control program in which all centers were requested to
verify data that appeared inconsistent or erroneous.
Although chest x-ray interpretation was performed by
on-site clinicians, which potentially increased variability,
we attempted to standardize interpretation by offering all
the investigators web-based training. Another limitation is
the lack of data collection concerning the use of conserva-
tive fluid strategy. Lastly, our assumption that patients dis-
charged from the hospital before day 28 were alive at that
time point is a further limitation.
Conclusions
Among ICUs in 50 countries, the period prevalence of ARDS
was 10.4% of ICU admissions. This syndrome appeared to be
underrecognized, undertreated, and associated with a high
mortality rate. These findings indicate the potential for im-
provement in management of patients with ARDS.
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